Mycophenolate mofetil in patients with hepatitis C virus infection

Lupus

Volumn 14, Issue SUPPL. 1, 2005, Pages

  Ramos Casals, Manuel ^a,b   Font, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cryoglobulinemia; Extrahepatic manifestations; Hepatitic C virus; Lymphoma; Mycophenolate mofetil

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; CHOLESTASIS; CLINICAL FEATURE; CYTOPENIA; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; MONOTHERAPY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; VASCULITIS;

EID: 16244386217     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2122oa     Document Type: Article

References (59)

1. Lipsky JJ. Mycophenolate mofetil. Lancet 1996; 348: 1357-1359.
2. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999; 68: 391-396.
3. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
4. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-283.
5. Klupp J, Glanemann M, Bechstein WO et al. Mycophenolate mofetil in combination with tacrolimus versus Neoral after liver transplantation. Transplant Proc 1999; 31: 1113-1114.
6. DiBisceglie AM, McHutchison J, Rice CM. New therapeutic strategies for hepatitis C. Hepatology 2002; 35: 224-231.
7. Neyts J, Meerbach A, McKenna P, De Clercq E. Use of yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 1996; 30: 125-132.
8. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8(Suppl 1): S19-S27.
9. Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990; 12: 1132-1146.
10. Fasola CG, Klintmalm GB. Hepatitis C and mycophenolate mofetil - a clarification. Liver Transpl 2002; 8: 411-412.
11. Platz KP, Mueller AR, Willimski B et al. Indications for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation. Transpl Proc 1998; 30: 1468-1469.
12. Ong JP, Barnes DS, Younossi ZM et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999; 30: 1293-1298.
13. Rostaing L, Izopet J, Sandres K, Cisterne JM, Fuel J, Durand D. Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 2000; 69: 991-994.
14. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
15. Eason JD, Loss GE, Blazek J, Nair S, Mason AL. Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial. Liver Transpl 2001; 7: 693-697.
16. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210.
17. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684.
18. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after liver transplantation. Gastroenterology 2002; 122: 889-896.
19. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820.
20. Boker KHW, Dalley G, Bahr MJ et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203-210.
21. Feray C, Gigou M, Samuel D et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137-1143.
22. Ghobrial RM, Farmer DG, Baquerizo A et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999; 229: 824-833.
23. Ghobrial RM, Steadman R, Gornbein J et al. A 10 year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384-393.
24. Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442-450.
25. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 40-46.
26. Burak KW, Kremers WK, Barts KP et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8: 362-369.
27. Nelson DR, Soldevila-Pico C, Reed A et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 1064-1070.
28. Gane EJ, Naoumov NV, Qian KP et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-177.
29. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5(suppl): S107-S114.
30. Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-34.
31. Wietzke-Braun P, Braun F, Sattler B, Ramadori G, Ringe B. Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis c virus related cirrhosis. World J Gastroenterol 2004; 10: 2213-2217.
32. Langrehr JM, Neumann UP, Lang M et al. First results from a prospective randomized trial comparing steroid-free induction therapy with tacrolimus and MMF versus tacrolimus and steroids in patients after liver transplantation for HCV. Transplant Proc 2002; 34: 1565-1566.
33. Breitenfeldt MK, Rasenack J, Berthold H et al. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130-136.
34. Abbott KC, Bucci JR, Matsumoto CS et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2908-2918.
35. Sumethkul V, Ingsathit A, Leelasa-Nguan P, Jirasiritham S. Use of mycophenolate mofetil in kidney transplant recipients with viral hepatitis infection: is it justified? Transplant Proc 2002; 34: 3217-3219.
36. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
37. Gumber SC, Chopra S. Hepatitic C: a multifaceted disease. Ann Intern Med 1995; 123: 615-620.
38. Ramos-Casals M, Font J, Ingelmo M. Prevalence and clinical significance of hepatitis C virus infection in systemic autoimmune diseases. Med Clin (Barc) 2001; 116: 701-709.
39. Ramos-Casals M, Loustaud-Ratti V, Zeher M. Hepatitits C virus and autoimmune diseases. In Ramos-Casals M, Garcia-Carrasco M, Rosas J, Calvo J, Font J editors. Masson: Barcelona 2005 (in press).
40. Ramos-Casals M, Trejo O, Garcia-Carrasco M, Font J. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford) 2003; 42: 818-828.
41. Hernández F, Blanquer A, Linares M, López A, Tarín F, Cerveró A. Autoimmune thrombocytopenia associated with hepatitis C virus infection. Acta Haematol 1998; 99: 217-220.
42. Linares M, Cerveró A, Colomina P et al. Chronic idiopathic thrombocytopenic purpura in the elderly. Acta Haematol 1995; 93: 80-82.
43. Saab S, Martin P. Hemolytic anemia and the treatment of chronic hepatitis C. J Clin Gastroenterol 1999; 28: 289-290.
44. Ramos-Casals M, Garcia-Carrasco M, Lopez-Medrano F et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore) 2003; 82: 87-96.
45. den Ottolander GJ, Gratama JW, de Koning J, Brand A. Long-term follow-up study of 168 patients with immune thrombocytopenia: implications for therapy. Scand J Haematol 1984; 32: 101-110.
46. DiFino SM, Lachant NA, Kirshner JJ, Gottlieb AJ. Adult idiopathic thrombocytopenic purpura: clinical findings and response to therapy. Am J Med 1980; 69: 430-442.
47. George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
48. Magrin S, Craxi A, Fabiano C et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-α or corticosteroid treatment. Hepatology 1994; 19: 273-279.
49. Ierardi E, Rendina M, Francavilla R et al. Mycophenolate mofetil in the treatment of autoimmune HCV-associated haematological disorders showing steroid resistance or dependence. J Viral Hepat 2003; 10: 390-393.
50. Trejo O, Ramos-Casals M, Garcia-Carrasco M et al. Cryoglobulinemia: Study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore) 2001; 80: 252-262.
51. Zuckerman E, Keren D, Slobodin G et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-α. J Rheumatol 2000; 27: 2172-2178.
52. Cacoub P, Maisonobe T, Gatel A, Servan J, Musset L, Piette JC. Systemic vasculitis in patients with hepatitis C. J Rheumatol 2001; 28: 109-118.
53. Cacoub P, Lidove O, Maisonobe T et al. Interferon-α and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002; 46: 3317-3326.
54. Ferri C, Moriconi L, Gremignai G et al. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986; 43: 246-253.
55. Karmochkine M, Bussel A, Leon A, Jarrousse B, Baudelot J, Guillevin L. Long-term plasma exchange. Analysis of indications, outcome and side effects. Ann Med Interne (Paris) 1994; 145: 373-375.
56. Gross WL. New concepts in treatment protocols for severe systemic vasculitis. Curr Opin Rheumatol 1999; 11: 41-46.
57. Reed MJ, Alexander GJ, Thiru S, Smith KG. Hepatitis C-associated glomeralonephritis - a novel therapeutic approach. Nephrol Dial Transplant 2001; 16: 869-871.
58. Caponnetto C, Rossi E, Primavera A. Mycophenolate mofetil: A new immunosuppressive approach. Successful treatment in a case of myasthenia gravis associated with incomplete lupus erythematosus syndrome and hepatitis C virus infection. Eur Neurol 2001; 46: 53-54.
59. Medina F, Fuentes J, Carranza I et al. Mycophenolate mofetil: a potential treatment for diffuse prolipherative lupus nephritis and chronic hepatitis C virus. Arthritis Rheum 2004; 50(suppl): S415.